Παρακολούθηση
Ian Davis
Ian Davis
Monash University
Η διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα monash.edu - Αρχική σελίδα
Τίτλος
Παρατίθεται από
Παρατίθεται από
Έτος
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
35532014
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, ...
Journal of clinical oncology 28 (6), 1061-1068, 2010
30972010
Enzalutamide with standard first-line therapy in metastatic prostate cancer
ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ...
New England Journal of Medicine 381 (2), 121-131, 2019
14432019
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
The Lancet 397 (10276), 797-804, 2021
7692021
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
MD Galsky, JÁA Arija, A Bamias, ID Davis, M De Santis, E Kikuchi, ...
The Lancet 395 (10236), 1547-1557, 2020
7652020
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis, W Chen, H Jackson, P Parente, M Shackleton, W Hopkins, ...
Proceedings of the National Academy of Sciences 101 (29), 10697-10702, 2004
5462004
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
5392018
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update
CN Sternberg, RE Hawkins, J Wagstaff, P Salman, J Mardiak, CH Barrios, ...
European journal of cancer 49 (6), 1287-1296, 2013
5242013
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
4582020
Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ...
European urology 77 (4), 508-547, 2020
3942020
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
3932015
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma
TE Hutson, ID Davis, JPH Machiels, PL De Souza, S Rottey, B Hong, ...
Journal of Clinical Oncology 28 (3), 475-480, 2010
3612010
Breast and prostate cancer: more similar than different
GP Risbridger, ID Davis, SN Birrell, WD Tilley
Nature Reviews Cancer 10 (3), 205-212, 2010
3302010
Tumor antigen expression in melanoma varies according to antigen and stage
C Barrow, J Browning, D MacGregor, ID Davis, S Sturrock, AA Jungbluth, ...
Clinical Cancer Research 12 (3), 764-771, 2006
3192006
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
RJ Motzer, C Porta, NJ Vogelzang, CN Sternberg, C Szczylik, J Zolnierek, ...
The Lancet Oncology 15 (3), 286-296, 2014
3062014
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
A Kneebone, C Fraser-Browne, GM Duchesne, R Fisher, M Frydenberg, ...
The Lancet Oncology 21 (10), 1331-1340, 2020
3022020
Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma
S RAMDAVE, GW THOMAS, SU Berlangieri, DM Bolton, IAN Davis, ...
The Journal of urology 166 (3), 825-830, 2001
2652001
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery
M Schnurr, Q Chen, A Shin, W Chen, T Toy, C Jenderek, S Green, ...
Blood 105 (6), 2465-2472, 2005
2552005
The regulatory T cell–associated transcription factor FoxP3 is expressed by tumor cells
LM Ebert, BS Tan, J Browning, S Svobodova, SE Russell, N Kirkpatrick, ...
Cancer research 68 (8), 3001-3009, 2008
2512008
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised …
T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ...
The lancet oncology 23 (9), 1133-1144, 2022
2352022
Δεν είναι δυνατή η εκτέλεση της ενέργειας από το σύστημα αυτή τη στιγμή. Προσπαθήστε ξανά αργότερα.
Άρθρα 1–20